scholarly journals Prevalence of Arm Lymphedema among Patients with Breast Cancer Surgery

2016 ◽  
Vol 12 (3) ◽  
pp. 111-117
Author(s):  
Radha Acharya Pandey ◽  
Shilpa Shrestha
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Survivors ◽  
Radical Mastectomy ◽  
Cancer Therapeutics ◽  
Structured Interview ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Related Factors ◽  
Cross Sectional ◽  
Arm Lymphedema

Background & Objectives: Lymphedema is a common complication of cancer therapeutics; its prevalence, treatment outcomes, and costs have been poorly defined. It is potentially debilitating condition in breast cancer survivors which negatively affects the quality of life. This study aims to assess the prevalence of arm lymphedema among patients with breast cancer surgery.Materials & Methods: A cross-sectional study was conducted to assess the prevalence of arm lymphedema among the women with breast cancer surgery. Purposive sampling technique was used to collect the data from a sample of 66 women of selected hospitals.  Data were collected through self constructed structured and semi structured interview based questionnaire which consisted socio demographic information and clinical related factors. Results: Among The overall prevalence of arm lymphedema was found to be seven (10.6%) respondents among the study population. In this study, 41 (62.1%) respondents were < 50 years of age, 13 (19.7%) had education of secondary level, 27 (40.9%) had received radiation therapy, 63 (95.5%) had no history of infection, 54 (81.8%) had undergone modified radical mastectomy, and 56 (84.8%) had involved lymph node resection. Statistically no any significant association was found between these variables.Conclusion: On the basis of the findings, this conclusion has been drawn that prevalence of arm lymphedema among patients with breast cancer surgery was low (10.6%). Moreover no association was found between the prevalence of arm lymphedema, sociodemographic variables and clinical related factors.

scholarly journals Assessment of quality of life in women five years after breast cancer surgery, members of Breast Cancer Self-Help Groups – non-randomized, cross-sectional study

2018 ◽  
Vol 22 (1) ◽  
pp. 20-26 ◽  
Author(s):  
Magdalena Sowa ◽  
Iwona Głowacka-Mrotek ◽  
Ewelina Monastyrska ◽  
Tomasz Nowikiewicz ◽  
Magdalena Mackiewicz-Milewska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cross Sectional Study ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Sectional Study ◽  
Cross Sectional ◽  
Self Help ◽  
Self Help Groups

scholarly journals Dexmedetomidine as an Adjunctive Analgesic with Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery

2014 ◽  
Vol 5;17 (5;9) ◽  
pp. E589-E598 ◽  
Author(s):  
Sahar A. Mohamed
Keyword(s):  
Breast Cancer ◽  
Blood Pressure ◽  
Side Effects ◽  
Pulse Rate ◽  
Radical Mastectomy ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Postanesthesia Care Unit ◽  
Modified Radical Mastectomy ◽  
Group B

Background: There is little systematic research on the efficacy and tolerability of the addition of adjunctive analgesic agents in paravertebral analgesia. The addition of adjunctive analgesics, such as fentanyl and clonidine, to local anesthetics has been shown to enhance the quality and duration of sensory neural blockades, and decrease the dose of local anesthetic and supplemental analgesia. Objectives: Investigation of the safety and the analgesic efficacy of adding 1 µg/kg dexmedetomidine to bupivacaine 0.25% in thoracic paravertebral blocks (PVB) in patients undergoing modified radical mastectomy. Study Design: A randomized, double-blind trial. Setting: Academic medical center. Methods: Sixty American Society of Anesthesiologists physical status –I – III patients were randomly assigned to receive thoracicPVB with either 20 mL of bupivacaine 0.25% (Group B, n = 30), or 20 mL of bupivacaine 0.25% + 1 µg/kg dexmedetomidine (Group BD, n= 30). Assessment parameters included hemodynamics, sedation score, pain severity, time of first analgesics request, total analgesic consumption, and side effects in the first 48 hours. Results: There was a significant reduction in pulse rate and diastolic blood pressure starting at 30 minutes in both groups, but more evidenced in group BD (P < 0.001). Intraoperative Systolic blood pressure showed a significant reduction at 30 minutes in both groups (P < 0.001) then returned to baseline level at 120 minutes in both groups. There was a significant increase in pulse rate starting 2 hours postoperative until 48 hours postoperatively in group B but only after 12 hours until 48 hours in group BD (P < 0.001). The time of the first rescue analgesic requirement was significantly prolonged in the group BD (8.16 ± 42 hours) in comparison to group B (6.48 ± 5.24 hours) (P = 0.04). The mean total consumption of intravenous tramadol rescue analgesia in the postanesthesia care unit in the firtst 48 hours postoperatively was significantly decreased in group BD (150.19 ± 76.98 mg) compared to group B (194.44 ± 63.91 mg) (P = 0.03). No significant serious adverse effects were recorded during the study. Limitations: This study is limited by its sample size. Conclusion: The addition of dexmedetomidine 1 µg/kg to bupivacaine 0.25% in thoracic PVB in patients undergoing modified radical mastectomy improves the quality and the duration of analgesia and also provides an analgesic sparing effect with no serious side effects. Key words: Dexmedetomidine, paravertebral block, postoperative analgesia, breast cancer surgery

scholarly journals Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors

JAMA Surgery ◽  
2020 ◽  
Vol 155 (11) ◽  
pp. 1035
Author(s):  
Shoshana M. Rosenberg ◽  
Laura S. Dominici ◽  
Shari Gelber ◽  
Philip D. Poorvu ◽  
Kathryn J. Ruddy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Well Being ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
Young Breast Cancer

scholarly journals Regulatory VCAN polymorphism is associated with shoulder pain and disability in breast cancer survivors

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Trevor S. Mafu ◽  
Alison V. September ◽  
Delva Shamley
Keyword(s):  
Breast Cancer ◽  
Cancer Survivors ◽  
Shoulder Pain ◽  
Breast Cancer Survivors ◽  
Individual Variability ◽  
Nucleotide Polymorphisms ◽  
Related Factors ◽  
Cross Sectional ◽  
Pain Disability ◽  
Increased Risk

Abstract Background and purpose Shoulder morbidity following breast cancer treatment is multifactorial. Despite several treatment- and patient-related factors being implicated, unexplained inter-individual variability exists in the development of such morbidity. Given the paucity of relavant genetic studies, we investigate the role of polymorphisms in candidate proteoglycan genes. Patients and methods We conducted a cross-sectional study on 254 South African breast cancer survivors, to evaluate associations between shoulder pain/disability and ten single nucleotide polymorphisms (SNPs) within four proteoglycan genes: ACAN (rs1126823 G>A, rs1516797 G>T, rs2882676 A>C); BGN (rs1042103 G>A, rs743641 A>T, rs743642 G>T); DCN rs516115 C>T; and VCAN (rs11726 A>G, rs2287926 G>A, rs309559). Participants were grouped into no–low and moderate–high shoulder pain/disability based on total pain/disability scores: < 30 and ≥ 30, respectively using the Shoulder Pain and Disability Index (SPADI). Results The GG genotype of VCAN rs11726 was independently associated with an increased risk of being in the moderate-to-high shoulder pain (P = 0.005, OR = 2.326, 95% CI = 1.259–4.348) or disability (P = 0.011, OR = 2.439, 95% CI = 1.235–4.762) categories, after adjusting for participants’ age. In addition, the T-T-G inferred allele combination of BGN (rs74364–rs743642)–VCAN rs11726 was associated with an increased risk of being in the moderate-to-high shoulder disability category (0 = 0.002, OR = 2.347, 95% CI = 1.215–4.534). Conclusion Our study is first to report that VCAN rs11726, independently or interacting with BGN polymorphisms, is associated with shoulder pain or disability in breast cancer survivors. Whereas our findings suggest an involvement of proteoglycans in the etiology of shoulder pain/disability, further studies are recommended.

scholarly journals Predictive Factors for Patients who Need Treatment for Chronic Post-Surgical Pain (CPSP) after Breast Cancer Surgery

2021 ◽  
Author(s):  
Yasuaki Uemoto ◽  
Megumi Uchida ◽  
Naoto Kondo ◽  
Yumi Wanifuchi-Endo ◽  
Takashi Fujita ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Recurrence ◽  
Japanese Version ◽  
Cancer Surgery ◽  
Breast Cancer Recurrence ◽  
Breast Cancer Surgery ◽  
Cross Sectional ◽  
Postsurgical Pain ◽  
Post Surgery ◽  
Chronic Postsurgical Pain

Abstract Purpose: Although chronic postsurgical pain (CPSP) after breast cancer surgery is a common and prevalent postsurgical adverse event, the need for CPSP treatment has not been investigated. This study examined the proportion of patients who needed treatment for CPSP and associated predictors. Methods: We conducted a cross-sectional study with female patients who underwent breast cancer surgery at our institution. Participants were aged ≤65 years at the time of this study and were at least 1 year post surgery. The questionnaire examined the presence of and need for treatment for CPSP and included the Japanese version of the Concerns about Recurrence Scale (CARS-J). Multivariate analyses were used to identify independent predictors of needing treatment for CPSP.Results: In total, 305 patients completed the questionnaire. The mean time since surgery was 67.1 months; 151 (51%) patients developed CPSP after breast cancer surgery and 61 (39%) needed treatment for CPSP. Among patients that developed CPSP, the fear of breast cancer recurrence as assessed by the CARS-J (odds ratio [OR] 2.22, 95% confidence interval [CI]: 1.30–3.81, P=0.004) and >2 postsurgical pain regions (OR 2.52, 95% CI: 1.16–5.57, P=0.020) were independent predictors of needing treatment for CPSP.Conclusions: This study is the first to identify the proportion and predictors of patients who need treatment for CPSP. Fear of breast cancer recurrence and >2 postsurgical pain regions may predict the need for CPSP treatment among patients following breast cancer surgery.

scholarly journals Factors influencing non–adherence to chemotherapy: Perspective of Nigerian breast cancer survivors

2019 ◽  
Author(s):  
Justin-Agorye Ingwu ◽  
Chiamaka Idoko ◽  
Chidinma-Egbichi Israel ◽  
Ijeoma Maduakolam ◽  
Obiagele Madu
Keyword(s):  
Breast Cancer ◽  
Health Care ◽  
Cancer Survivors ◽  
Breast Cancer Survivors ◽  
Health Care Policy ◽  
Clinic Visit ◽  
Related Factor ◽  
Duration Of Treatment ◽  
Related Factors ◽  
Cross Sectional

Background & Aim: The use of chemotherapy for the treatment of breast cancer has experienced a rapid increase in recent years and this is expected to continue. The objectives of the study were to ascertain the patient-related factors, therapy related factors, and health care system factors that influence non-adherence to chemotherapy among breast cancer survivors at University of Nigeria Teaching Hospital (UNTH), Enugu. Methods & Materials: The study design was a cross-sectional descriptive survey with a total population of 100 cancer survivors. The breast cancer questionnaire was the instrument used for data collection. Results: The result of the study showed that financial constraint 61(61.0%) was the major patient related factor that influence non-adherence to chemotherapy, medication side effects (hair loss, loss of weight) 62(62.0%) and duration of treatment 50(50.0%) were the major therapy related factors while unfavorable hour of clinic visit 40(40.0%) was the major health care related factor that influences non-adherence to chemotherapy. Conclusion: It was concluded that the federal government should re-implement the health care policy that allowed treatment free-of-charge at Nigerian government hospitals to those with malignancies and other chronic ailments to mitigate the burden of associated financial problems and encourage patients to seek orthodox medical care. Also, health education initiation on benefit of adhering to chemotherapy would be needed on the part of the nurses to foster the women intake of chemotherapy. Nurses caring for women who receive endocrine therapy for breast cancer should identify those who may be at greater risk for being non-adherent.

scholarly journals Progressive resistance training to prevent arm lymphedema in the first year after breast cancer surgery: Results of a randomized controlled trial

Cancer ◽  
2019 ◽  
Vol 125 (10) ◽  
pp. 1683-1692 ◽  
Author(s):  
Gunn Ammitzbøll ◽  
Christoffer Johansen ◽  
Charlotte Lanng ◽  
Elisabeth Wreford Andersen ◽  
Niels Kroman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Randomized Controlled Trial ◽  
Resistance Training ◽  
Controlled Trial ◽  
Cancer Surgery ◽  
Breast Cancer Surgery ◽  
First Year ◽  
Progressive Resistance Training ◽  
Randomized Controlled ◽  
Arm Lymphedema
Sign in / Sign up

Export Citation Format

Share Document